Methotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas
Authors:
- 6 December 2010
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 52 (3) , 521-524
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialThe Lancet, 2009
- Efficacy and tolerability of high‐dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in childrenBritish Journal of Haematology, 2007
- CNS or Bone Marrow Involvement As Risk Factors for Poor Survival in Post-Transplantation Lymphoproliferative Disorders in Children After Solid Organ TransplantationJournal of Clinical Oncology, 2007
- Primary CNS LymphomaJournal of Clinical Oncology, 2006
- Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocolAnnals of Oncology, 2005
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS LymphomaJournal of Clinical Oncology, 2005
- Primary Central Nervous System Posttransplant Lymphoproliferative DisordersAmerican Journal of Clinical Pathology, 2004
- Primary brain lymphomas after kidney transplantation: presentation and outcomeTransplantation, 2003
- Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative DisordersJournal of Clinical Oncology, 2001
- Central Nervous System Lymphomas In Organ Allograft RecipientsTransplantation, 1995